Effects of ATPM-ET, a novel |[kappa]| agonist with partial |[mu]| activity, on physical dependence and behavior sensitization in mice
Jian-feng Sun,Yu-hua Wang,Fu-ying Li,Gang Lu,Yi-min Tao,Yun Cheng,Jie Chen,Xue-jun Xu,Zhi-qiang Chi,John L Neumeyer,Ao Zhang,Jing-gen Liu
DOI: https://doi.org/10.1038/aps.2010.164
IF: 7.169
2010-01-01
Acta Pharmacologica Sinica
Abstract:Opioid analgesic drugs, such as morphine, are widely used for the relief of severe pain. However, repeated use of morphine can induce tolerance and addiction (physical and psychological dependence)1, 2. Indeed, opioid addiction persists as a major public health problem3, 4, 5. Although much progress has been made, therapeutic strategies for the treatment of opioid addiction are still limited, largely due to the poor understanding of the mechanisms contributing to opioid addiction. Hence, it is necessary to further explore the neural mechanisms underlying opioid addiction and to develop new strategies for the treatment of opioid abuse. Numerous studies have suggested that the μ-opioid receptor plays a major role in opioid addiction, whereas κ-opioid agonists may have therapeutic potential for opioid addiction. For example, previous studies in both nonhuman primates and rats have demonstrated that κ agonists functionally attenuate many of the behavioral effects of cocaine, including place preference6, 7, 8, self-administration9, 10, 11, 12 and the reinstatement of extinguished drug-taking behavior in an animal model of relapse12, 13. However, these selective agonists produce many severe, undesirable side effects such as salivation, emesis, and sedation in nonhuman primates10, 11, which may limit the clinical utility of κ agonists for the treatment of drug abuse. Increasing evidence suggests that κ agonists with mixed activity at κ and μ receptors may be more promising candidates for drug abuse pharmacotherapy than highly selective κ agonists14, 15. Therefore, one potential treatment strategy for opioid addiction is to develop compounds with mixed activity at κ and μ receptors16, 17. A recent study from our group demonstrated that ATPM, a novel mixed κ agonist and μ agonist/antagonist, can reduce heroin self-administration with relatively low levels of sedation18. The present study was undertaken to examine the effects of ATPM-ET, a derivate of ATPM, on morphine-induced physical dependence and behavioral sensitization (Figure 1). Cell membranes were prepared as described in our previous report19. Cells were detached by incubation with phosphate-buffered saline containing 1 mmol/L EDTA and centrifuged at 1000×g for 10 min (4 °C). The cell pellet was suspended in ice-cold homogenization buffer composed of 50 mmol/L HEPES, pH 7.4, 1 mmol/L MgCl2, and 1 mmol/L EGTA. Cells were homogenized with 10 strokes using a glass Dounce homogenizer. After centrifugation at 40000×g for 10 min (4 °C), pellets were resuspended in homogenization buffer, homogenized, and centrifuged again. The final pellets were resuspended in 50 mmol/L Tris–HCl buffer, pH 7.4. Protein concentration was determined, and aliquots were stored at −80 °C. Mice were treated with morphine (10 mg/kg, subcutaneously) or saline for 7 consecutive days, and their activity was measured for 1 h after drug administration on days 1, 4, and 7. After a 7-d washout period, mice were challenged with morphine (10 mg/kg, subcutaneously), and their locomotor activity was measured for 1 h, as previously described20. Four groups of mice were injected with morphine (10 mg/kg, subcutaneously) for 7 consecutive days to induce behavioral sensitization, and one group of mice was injected with saline (10 mL/kg, subcutaneously). After 7 days of washout, mice were treated with either saline or ATPM-ET (0.75, 1.5, 3 mg/kg, subcutaneously) 15 min prior to morphine challenge (10 mg/kg, subcutaneously). The locomotor activity of the mice was then measured for 1 h. To characterize the agonist activity of ATPM-ET, [35S]GTPγS assays were performed with membranes prepared from CHO cells that had been stably transfected with either the κ- or the μ-opioid receptors. The maximal stimulatory response of (−)U50,488H and DAMGO was designated as the 100% effect for κ- and μ-opioid receptors, respectively. ATPM-ET produced a maximal stimulation (Emax) of 85% for the κ-opioid receptor and 36% for the μ-opioid receptor and exhibited an EC50 value of 1.7 nmol/L for the κ- and 61 nmol/L for the μ-opioid receptors (Table 1). The results of these [35S]GTPγS binding assays indicate that ATPM-ET acts as a high-efficacy κ-opioid receptor agonist and a low-efficacy μ-opioid receptor agonist. First, we established the induction of morphine sensitization in mice as described previously24. Mice were treated with saline or morphine (10 mg/kg, sc) once per day for 7 consecutive days. Locomotor activity was recorded for 1 h following drug administration on days 1, 4, and 7. As shown in Figure 3, the initial injection of morphine (10 mg/kg, subcutaneously) elicited a significant increase in locomotor activity when compared to an injection of saline. Daily morphine injections led to a progressive increase in locomotor activity, with significantly elevated locomotion on days 4 and 7 compared to day 1. A two-factor repeated measures ANOVA shows significant effects of both drug (F(1, 28)=211.2, P<0.001) and time of treatment (F(2, 28)=6.82, P<0.001) as well as an interaction between the drug and the time of treatment (F(2, 28)=7.05, P<0.001). In contrast, no enhancement of locomotor activity was observed in mice injected with saline for 7 days. These results indicate that morphine promotes the development of behavioral sensitization in mice, consistent with previous studies24. Next, we examined the effects of ATPM-ET on morphine-induced behavioral sensitization. After 7 days of washout, challenge with morphine (10 mg/kg, subcutaneously) induced a robust increase in locomotor activity in mice repeatedly treated with morphine (10 mg/kg) for 7 consecutive days compared to mice repeatedly injected with saline (P<0.01). One-way ANOVA revealed a significant effect of ATPM-ET on the expression of morphine sensitization (F(4, 37)=6.42, P<0.01). LSD post hoc tests indicated that treatment with ATPM-ET (1.5, 3 mg/kg, subcutaneously) 15 min before the morphine challenge significantly inhibited morphine-induced behavior sensitization (Figure 4, P<0.05). A great deal of research has focused on κ-opioid receptor agonists with activity at the μ-opioid receptor as potential compounds to treat drug addiction25, 26. It has been reported that compounds with mixed κ and μ activity decrease cocaine self-administration27, 28, 29. These findings suggest that κ agonists with μ-receptor activity may be promising medications for drug addiction. To further confirm the effects of κ-opioid agonists with activity at the μ-opioid receptor on drug addiction, we investigated the effects of ATPM-ET, an N-ethyl substituted aminothiazolomorphinan, on morphine physical dependence and the expression of morphine-induced behavioral sensitization in mice. Our current results demonstrate that ATPM-ET is a full κ agonist with partial μ agonist activity and that ATPM-ET displays a potent antinociceptive effect in mice in the hot plate test. The results from this study also show that the administration of ATPM-ET to chronic morphine-treated mice prior to naloxone precipitation significantly inhibits jumping and body weight loss induced by morphine withdrawal. However, consistent with previous studies19, 21, the classic κ1-opioid receptor agonist, (−)U50,488H, failed to inhibit withdrawal jumping and body weight loss induced by naloxone precipitation. Our findings support the hypothesis that κ agonists with partial μ agonist activity may have greater therapeutic benefits in the treatment of drug addiction. Acute or repeated morphine administration in rodents can enhance locomotor activity and cause behavioral sensitization, a long-lasting behavioral alteration that has been proposed to play a prominent role in some of the motivational aspects of drug addiction, such as craving and drug-seeking30. Consistent with previous studies31, 32, 33, we demonstrate that repeated administration of morphine can increase locomotor activity and induce behavioral sensitization. To further confirm that ATPM-ET may have utility for the treatment of drug abuse, we examined the effects of ATPM-ET on morphine-induced behavioral sensitization. The present study demonstrates that ATPM-ET dose-dependently inhibits the expression of behavioral sensitization induced by morphine treatment, which further supports that ATPM-ET may be a promising candidate agent for the treatment of drug abuse. In conclusion, ATPM-ET is a new aminothiazolomorphinan analog with mixed κ agonist and μ agonist activities that produces dose-dependent antinociception in the hot plate test. More importantly, ATPM-ET can attenuate morphine-induced physical dependence and inhibit morphine-induced behavioral sensitization. Thus, ATPM-ET is a potentially promising candidate for the treatment of opioid addiction. Jian-feng SUN designed and performed the research and wrote the paper; Yu-hua WANG, Gang LU, and Yun CHENG assisted in the research; Yi-min TAO, Xue-jun XU, and Jie CHEN helped with data analysis; Fu-ying LI, John L NEUMEYER, and Ao ZHANG provided the ATPM-ET; Zhiqiang CHI provided consultation; Jing-gen LIU designed the research and revised the paper. This work was supported by the National Basic Research Program grant from the Ministry of Science and Technology of China (2009CB522000, 2009ZX09301-001), National Natural Science Foundation of China (30873050) and a fund granted by the Chinese Academy of Sciences (KSCX2-YW-R-253).